FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912661196> ?p ?o ?g. }

• W2912661196 endingPage "e283" @default.
• W2912661196 startingPage "e275" @default.
• W2912661196 abstract "This study characterizes the tumor-immune microenvironment in pretreatment, localized anal squamous cell carcinoma (ASCC), including two markers that have not previously been studied in ASCC: indoleamine 2,3 dioxygenase 1 (IDO1) and human leukocyte antigen (HLA) class I.Retrospective review identified 63 patients with ASCC receiving definitive chemoradiation between 2005 and 2016 with pretreatment tissue available. Immunohistochemistry was used to quantify cluster of differentiation 8 (CD8), programmed cell death protein 1, programmed death-ligand 1, HLA class I, and IDO1. Cox proportional hazards models evaluated associations between outcomes and immune markers, controlling for clinical characteristics.With a median follow-up of 35 months, 3-year overall survival was 78%. The only marker found to have a robust association with outcome was tumor IDO1. In general, the percentage of tumor cells expressing IDO1 was low (median 1%, interquartile range 0%-20%); however, patients with >50% of tumor cells expressing IDO1 had significantly worse overall survival (hazard ratio [HR] 4.7, p = .007) as well as higher local recurrence (HR 8.6, p = .0005) and distant metastasis (HR 12.7, p = .0002). Tumors with >50% IDO1 were also more likely to have the lowest quartile of CD8 infiltrate (<40 per high-power field, p = .024).ASCC has a diverse immune milieu. Although patients generally do well with standard therapy, IDO1 may serve as a prognostic indicator of poor outcome and could help identify a patient population that might benefit from IDO-targeted therapies.After definitive chemoradiation, patients with locally advanced anal cancer may experience significant treatment morbidity and high risk of recurrence. The goal of the current study is to identify novel prognostic factors in the tumor-immune microenvironment that predict for poor outcomes after definitive chemoradiation. This study characterizes the tumor-immune microenvironment in pre-treatment, localized anal squamous cell carcinoma (ASCC), including two markers which have not previously been studied in ASCC: indoleamine 2,3 dioxygenase 1 (IDO1) and HLA class I. With a median follow-up of 3 years, this study demonstrated that high IDO1 expression is correlated with significantly worse 3-year overall survival (88% vs. 25%). Whereas recent studies of IDO1 inhibitors have shown mixed results, this study suggests that patients with anal cancer with high IDO1 expression have dismal prognosis and may represent a patient population primed for response to targeted IDO1 inhibition." @default.
• W2912661196 created "2019-02-21" @default.
• W2912661196 creator A5009112537 @default.
• W2912661196 creator A5012704679 @default.
• W2912661196 creator A5018624284 @default.
• W2912661196 creator A5034115525 @default.
• W2912661196 creator A5038972103 @default.
• W2912661196 creator A5044225007 @default.
• W2912661196 creator A5070720153 @default.
• W2912661196 creator A5073123534 @default.
• W2912661196 creator A5073757407 @default.
• W2912661196 creator A5074136628 @default.
• W2912661196 creator A5077760288 @default.
• W2912661196 creator A5079599874 @default.
• W2912661196 creator A5081890512 @default.
• W2912661196 creator A5083203430 @default.
• W2912661196 creator A5088474933 @default.
• W2912661196 date "2019-02-12" @default.
• W2912661196 modified "2023-10-16" @default.
• W2912661196 title "High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy" @default.
• W2912661196 cites W1560273623 @default.
• W2912661196 cites W1615200703 @default.
• W2912661196 cites W1666596826 @default.
• W2912661196 cites W1966064788 @default.
• W2912661196 cites W1973251492 @default.
• W2912661196 cites W1983050089 @default.
• W2912661196 cites W1985745369 @default.
• W2912661196 cites W2003635644 @default.
• W2912661196 cites W2007489575 @default.
• W2912661196 cites W2010378562 @default.
• W2912661196 cites W2029324508 @default.
• W2912661196 cites W2030923896 @default.
• W2912661196 cites W2050320008 @default.
• W2912661196 cites W2066861752 @default.
• W2912661196 cites W2067126590 @default.
• W2912661196 cites W2070281021 @default.
• W2912661196 cites W2076232020 @default.
• W2912661196 cites W2094530868 @default.
• W2912661196 cites W2108357035 @default.
• W2912661196 cites W2111762872 @default.
• W2912661196 cites W2127903252 @default.
• W2912661196 cites W2128978912 @default.
• W2912661196 cites W2141269240 @default.
• W2912661196 cites W2148567638 @default.
• W2912661196 cites W2157620815 @default.
• W2912661196 cites W2158244375 @default.
• W2912661196 cites W2164644812 @default.
• W2912661196 cites W2164710273 @default.
• W2912661196 cites W2188878935 @default.
• W2912661196 cites W2220882815 @default.
• W2912661196 cites W2224538875 @default.
• W2912661196 cites W2306443763 @default.
• W2912661196 cites W2512604775 @default.
• W2912661196 cites W2529484692 @default.
• W2912661196 cites W2555574167 @default.
• W2912661196 cites W2587589421 @default.
• W2912661196 cites W2589072142 @default.
• W2912661196 cites W2621587943 @default.
• W2912661196 cites W2766016099 @default.
• W2912661196 cites W2772627340 @default.
• W2912661196 doi "https://doi.org/10.1634/theoncologist.2018-0794" @default.
• W2912661196 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6656510" @default.
• W2912661196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30755500" @default.
• W2912661196 hasPublicationYear "2019" @default.
• W2912661196 type Work @default.
• W2912661196 sameAs 2912661196 @default.
• W2912661196 citedByCount "16" @default.
• W2912661196 countsByYear W29126611962019 @default.
• W2912661196 countsByYear W29126611962020 @default.
• W2912661196 countsByYear W29126611962021 @default.
• W2912661196 countsByYear W29126611962023 @default.
• W2912661196 crossrefType "journal-article" @default.
• W2912661196 hasAuthorship W2912661196A5009112537 @default.
• W2912661196 hasAuthorship W2912661196A5012704679 @default.
• W2912661196 hasAuthorship W2912661196A5018624284 @default.
• W2912661196 hasAuthorship W2912661196A5034115525 @default.
• W2912661196 hasAuthorship W2912661196A5038972103 @default.
• W2912661196 hasAuthorship W2912661196A5044225007 @default.
• W2912661196 hasAuthorship W2912661196A5070720153 @default.
• W2912661196 hasAuthorship W2912661196A5073123534 @default.
• W2912661196 hasAuthorship W2912661196A5073757407 @default.
• W2912661196 hasAuthorship W2912661196A5074136628 @default.
• W2912661196 hasAuthorship W2912661196A5077760288 @default.
• W2912661196 hasAuthorship W2912661196A5079599874 @default.
• W2912661196 hasAuthorship W2912661196A5081890512 @default.
• W2912661196 hasAuthorship W2912661196A5083203430 @default.
• W2912661196 hasAuthorship W2912661196A5088474933 @default.
• W2912661196 hasBestOaLocation W29126611961 @default.
• W2912661196 hasConcept C119060515 @default.
• W2912661196 hasConcept C121608353 @default.
• W2912661196 hasConcept C126322002 @default.
• W2912661196 hasConcept C143998085 @default.
• W2912661196 hasConcept C167672396 @default.
• W2912661196 hasConcept C203014093 @default.
• W2912661196 hasConcept C207103383 @default.
• W2912661196 hasConcept C2776107976 @default.
• W2912661196 hasConcept C2778424827 @default.
• W2912661196 hasConcept C2779840525 @default.

• next